المؤلفون: Piercarlo Saletti, M. Wernli, Hanspeter Honegger, Monica Castiglione-Gertsch, Richard Herrmann, Silvia Hanselmann, Peter Brauchli, Roger Stupp, Markus Borner, B. Pestalozzi, A. Roth, Rudolf Morant, Aron Goldhirsch, Samuel Müller, Daniel Dietrich

المصدر: Journal of Clinical Oncology, Vol. 20, No 7 (2002) pp. 1759-66

مصطلحات موضوعية: Male, Cancer Research, Organoplatinum Compounds, Colorectal cancer, Antimetabolites, Antineoplastic/administration & dosage, medicine.medical_treatment, Phases of clinical research, Gastroenterology, Deoxycytidine, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil/analogs & derivatives, ddc:616, ddc:617, Colorectal Neoplasms/drug therapy, Middle Aged, Oxaliplatin, Treatment Outcome, Oncology, Tolerability, Diarrhea/chemically induced, Female, Fluorouracil, Colorectal Neoplasms, medicine.drug, Adult, Diarrhea, medicine.medical_specialty, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use, Adenocarcinoma, Drug Administration Schedule, Capecitabine, Adenocarcinoma/drug therapy, Internal medicine, medicine, Deoxycytidine/administration & dosage/analogs & derivatives, Humans, Organoplatinum Compounds/administration & dosage, Aged, Neoplasm Staging, Chemotherapy, Performance status, business.industry, medicine.disease, digestive system diseases, Surgery, Regimen, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e51a7d0fa4e25d9b80773267cff71a9
https://pubmed.ncbi.nlm.nih.gov/11919232